Pharming Announces Topline Study Results On Prophylactic Use Of Ruconest In Hereditary Angioedema
Leiden, The Netherlands, November 29, 2010. Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announced the results of its exploratory Phase II study on the safety and prophylactic effect of recombinant human C1 inhibitor (“rhC1INH”) in patients with Hereditary Angioedema (HAE).
The study is an open-label exploratory phase II study of the safety and prophylactic effect of a weekly 50 U/kg rhC1INH treatment in asymptomatic patients with hereditary C1INH deficiency (the “OPERA study”). In the study, 25 asymptomatic HAE patients with a history of frequent attacks received once weekly administrations of 50 U/kg of Ruconest for 8 weeks. Patients reported a median of 60 HAE attacks (range 39 to 467) over the past two years, corresponding to an averag e of 0.6 attacks per week (range 0.4 to 4.5). The breakthrough attack rate observed during the study was much lower with a median of 2 attacks over the 8 week period, corresponding to an average of 0.25 attacks per week (range 0 to 1.5). Weekly administrations of 50 U/kg rhC1INH was generally safe and well tolerated.
Dr. Rienk Pijpstra, Chief Medical Officer of Pharming: “The results of this exploratory study suggest that Ruconest, in addition to the approved indication in Europe for the acute treatment of angioedema attacks, could also offer significant value for long term prophylaxis in patients with frequent attacks. We plan further pharmacological investigations to optimize Ruconest dose and dosing interval for this indication.”
In October, the European Commission granted Pharming Marketing Authorization for its lead product Ruconest for the treatment of acute attacks of Hereditary Angioedema. Pharming’s marketing and distribution partner Swedish Orphan Biovitrum is preparing this year’s launch of Ruconest initially in Germany, the UK, Sweden, Finland and Denmark, followed by a rolling launch in each of the other European Area countries covered by the agreement.
About HAE and Ruconest™ (Rhucin® in non-European countries)
HAE is a human genetic disorder in which the patient is deficient in or lacks a functional plasma protein C1 inhibitor, resulting in an overreaction of the immune system. The disease is characterized by unpredictable and debilitating episodes of intense swelling of the extremities, face, trunk, genitals, abdomen and upper airway, which may last up to five days when untreated. In addition to the life-threatening nature of the disease in case of laryngeal attacks, quality of life for individuals with the disease may be seriously impaired. Approximately one in 30,000 individuals (1:10,000 ? 1:50,000) suffers from HAE with an average of ap proximately eight acute attacks per year.
Ruconest is a recombinant version of the human C1 inhibitor (C1INH) protein approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein. The product is produced through Pharming’s proprietary technology in milk of transgenic rabbits.
Recent PHARM News
- Pharming Group reports second quarter and first half 2024 financial results and provides business update • GlobeNewswire Inc. • 08/01/2024 05:00:00 AM
- Pharming Group to report second quarter and first half 2024 financial results on August 1 • GlobeNewswire Inc. • 07/18/2024 06:00:00 AM
- Pharming Group to participate in June investor conferences • GlobeNewswire Inc. • 06/03/2024 06:00:00 AM
- Pharming Group to participate in June investor conferences • GlobeNewswire Inc. • 06/03/2024 06:00:00 AM
- Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union • GlobeNewswire Inc. • 05/30/2024 08:44:24 PM
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 05/21/2024 03:30:14 PM
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 05/21/2024 03:30:14 PM
- Pharming Group to participate in May investor conference • GlobeNewswire Inc. • 05/20/2024 06:00:00 AM
- Pharming Group to participate in May investor conference • GlobeNewswire Inc. • 05/20/2024 06:00:00 AM
- Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 05/15/2024 05:00:00 AM
- Pharming Group reports first quarter 2024 financial results and provides business update • GlobeNewswire Inc. • 05/08/2024 05:00:00 AM
- Pharming Group reports first quarter 2024 financial results and provides business update • GlobeNewswire Inc. • 05/08/2024 05:00:00 AM
- Pharming Group to report first quarter 2024 financial results on May 8 • GlobeNewswire Inc. • 04/24/2024 06:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/19/2024 04:43:36 PM
- Pharming Group announces the placement of €100 million convertible bonds due 2029 • GlobeNewswire Inc. • 04/18/2024 01:04:30 PM
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/18/2024 06:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming Group announces the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/04/2024 06:30:00 AM
- Pharming Group announces the filing of its 2023 Annual Report and Form 20-F • GlobeNewswire Inc. • 04/04/2024 05:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
- Pharming Group reports fourth quarter and full year 2023 financial results • GlobeNewswire Inc. • 03/14/2024 06:00:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM